噬菌體療法市場－全球產業規模、佔有率、趨勢、機會及預測（依細菌類型、產品、應用、地區及競爭格局分類，2021-2031年）

全球噬菌體療法市場預計將從 2025 年的 6,441 萬美元成長到 2031 年的 8,173 萬美元，複合年成長率為 4.05%。

噬菌體療法是指利用噬菌體（一種能夠標靶、感染並裂解特定致病菌的病毒）進行治療。推動這一市場發展的主要因素是全球範圍內抗菌素抗藥性（AMR）的日益普遍，這使得許多傳統抗生素對多重抗藥性菌株失效，從而促使人們尋求不依賴傳統抗菌機制的替代治療方法。這促進了基於噬菌體的解決方案在臨床和農業領域的應用。

儘管生物製藥市場潛力巨大，但缺乏標準化的法規結構是其商業性發展的一大障礙，因為現有的核准流程往往無法適應不斷發展的病毒療法。這種監管的不確定性阻礙了候選藥物的臨床試驗進程。世界衛生組織（WHO）報告稱，到2024年，全球處於臨床階段的抗菌藥物研發管線共有97種藥物，其中40種被歸類為非傳統治療方法，例如噬菌體。這項數據表明，業界正致力於開發新型生物療法以對抗抗藥性感染疾病。

市場促進因素

基因工程和合成噬菌體開發的技術進步正在從根本上改變市場格局，克服天然噬菌體的限制。 CRISPR-Cas3技術的應用使得人們能夠創造出精準設計的噬菌體，這些噬菌體比野生型噬菌體更有效地破壞目標細菌DNA，從而提高了其對抗多重抗藥性病原體的療效。這項變革得益於公共部門的大力支持。例如，2024年1月，Locus Biosciences公司宣布獲得美國生物醫學高級研究與發展局（BARDA）2,390萬美元的資金籌措，用於支持其基於CRISPR技術的噬菌體療法的第二期臨床試驗。這項進展旨在應對一項重大的醫學挑戰：尿道感染每年影響全球約1.5億人。

策略聯盟和創業投資投資為加速臨床研發提供了至關重要的資金。隨著商業環境的日趨成熟，整合正成為降低研發風險、確保後期臨床試驗資源的關鍵策略，近期一些旨在整合臨床資產並吸引機構投資者的引人注目的併購案例便印證了這一點。 BiomX公司宣布，該公司於2024年3月與Adaptive Phage Therapeutics簽署了合併協議，並同時獲得了5000萬美元的資金籌措，用於推進合併後公司的二期臨床試驗項目。這筆資金注入對於將噬菌體療法從實驗性、同情用藥階段轉化為商業性化藥物至關重要。

市場挑戰

生物製藥法規結構的缺失嚴重阻礙了全球噬菌體療法市場的發展。與傳統化學抗生素不同，噬菌體是具有基因進化能力的動態生物實體，而目前的核准流程主要針對靜態藥物化合物。這種不一致迫使研發人員應對不當的合規要求，導致研發週期延長，且安全性和有效性的評估標準難以預測。此外，缺乏噬菌體特異性特性的統一指南，也使臨床試驗更加複雜，並導致生產商難以向習慣於固定配方藥物的監管機構證明批次間的一致性。

這種監管上的不確定性造成了高風險環境，嚴重抑制了金融投資，阻礙了商業性擴張。投資人往往不願將資金投入風險較高、上市核准路徑不明朗的研究領域。根據生物技術與創新組織（BIO）統計，截至2024年，專注於感染疾病項目的公司在過去十年中僅獲得了生物製藥公司總創業投資投資的3.4%，造成了巨大的資金缺口，限制了噬菌體研發者應對複雜監管環境所需的資源。這實際上阻礙了有前景的候選療法走向商業化。

市場趨勢

將人工智慧 (AI) 應用於噬菌體發現領域，正從根本上改變研發格局，加速高特異性病毒候選物的鑑定。研發人員利用機器學習演算法篩檢龐大的基因組庫並預測噬菌體與宿主的相互作用，顯著降低傳統濕實驗室分離方法所需的時間和成本。這項技術進步能夠快速產生最佳化的噬菌體混合物，比人工匹配方法更有效地繞過細菌抗藥性機制，標誌著噬菌體發現正向運算驅動型轉變。根據《法國科技雜誌》報道，Phagos 公司於 2025 年 10 月完成 A 輪資金籌措，籌集 2,500 萬歐元，用於擴展其人工智慧驅動的平台，以開發不斷發展的精準噬菌體藥物。

同時，動物健康領域近期監管的成功正推動噬菌體技術向獸醫和農業領域擴張，並將市場範圍拓展至人類治療之外。隨著全球對畜牧業抗生素使用的限制日益嚴格，以應對「同一健康」挑戰，相關人員正將噬菌體添加劑商業化，以確保食品安全並改善動物福利。該領域目前正取得一系列監管里程碑，為更廣泛的商業性應用鋪路。例如，Intralytix公司報告稱，該公司於2025年9月獲得了美國食品藥物管理局（FDA）獸藥中心對其用於寵物食品加工的沙門氏菌特異性噬菌體核准的正式批准。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球噬菌體療法市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依細菌類型（沙門氏菌、噬菌體、鏈球菌、大腸桿菌等）
  • 依產品類型（口服、外用、手術治療）
  • 按應用領域（人類醫學、獸醫學、食品飲料、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美噬菌體療法市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲噬菌體療法市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區噬菌體療法市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲噬菌體療法市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲噬菌體療法市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球噬菌體療法市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Armata Pharmaceuticals, Inc.
• iNtODEWORLD, Inc.
• Phage International, Inc.
• Fixed-Phage Limited
• OCUS BIOSCIENCES, INC.
• Intralytix, Inc
• PhagoMed Biopharma GmbH
• PHAGELUX, INC.
• Pherecydes Pharma SADIR
• Adaptive Phage Therapeutics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Phage Therapy Market is projected to expand from USD 64.41 Million in 2025 to USD 81.73 Million by 2031, reflecting a compound annual growth rate (CAGR) of 4.05%. Phage therapy involves the therapeutic use of bacteriophages, viruses capable of specifically infecting and lysing targeted bacterial pathogens. A primary catalyst for this market is the escalating global prevalence of antimicrobial resistance (AMR), which has rendered many conventional antibiotics ineffective against multi-drug resistant strains; consequently, there is an intensified demand for alternative treatments that function independently of traditional antimicrobial mechanisms, fostering the development of phage-based solutions for both clinical and agricultural applications.

Despite the market's potential, the lack of a standardized regulatory framework for biological agents poses a significant barrier to commercial growth, as existing approval pathways are often poorly adapted for evolving viral therapies. This regulatory uncertainty complicates the advancement of candidates through clinical trials. Highlighting the sector's developmental activity, the World Health Organization reported that in 2024, the global clinical antibacterial pipeline included 97 agents, 40 of which were categorized as non-traditional therapeutics including bacteriophages, a statistic that underscores the industry's transition toward novel biological interventions to combat resistant infections.

Market Driver

Technological advancements in genetic engineering and synthetic phage development are fundamentally transforming the market by surmounting the limitations of naturally occurring bacteriophages. The incorporation of CRISPR-Cas3 technologies facilitates the creation of precision-engineered phages that destroy targeted bacterial DNA more effectively than wild-type counterparts, thereby improving efficacy against multidrug-resistant pathogens. This shift is supported by substantial public sector backing; for instance, according to Locus Biosciences, in January 2024, the company announced the receipt of $23.9 million in funding from the Biomedical Advanced Research and Development Authority to support the Phase 2 trial of its CRISPR-engineered bacteriophage therapy, a development that addresses a major medical burden given that an estimated 150 million people worldwide are affected by urinary tract infections annually.

Strategic collaborations and rising venture capital inflows are providing the essential capital to accelerate clinical pipelines. As the commercial landscape matures, consolidation has emerged as a key strategy for mitigating development risks and securing the resources necessary for late-stage trials, a trend illustrated by recent high-profile mergers aimed at pooling clinical assets and attracting institutional investment. According to BiomX Inc., in March 2024, the company finalized a merger agreement with Adaptive Phage Therapeutics while concurrently securing $50 million in financing to advance their combined Phase 2 clinical programs, financial injections that are critical for transitioning phage therapies from experimental compassionate use into commercially viable pharmaceutical products.

Market Challenge

The lack of a standardized regulatory framework for biological agents acts as a critical impediment to the growth of the Global Phage Therapy Market. Unlike traditional chemical antibiotics, bacteriophages are dynamic biological entities capable of genetic evolution, whereas current approval pathways are predominantly designed for static medicinal compounds. This misalignment forces developers to navigate ill-suited compliance requirements, resulting in prolonged development timelines and unpredictable criteria for establishing safety and efficacy, while the absence of harmonized guidelines addressing the unique properties of phages increases the complexity of clinical trials and makes it difficult for manufacturers to prove batch consistency to regulators accustomed to fixed formulations.

This regulatory ambiguity creates a high-risk environment that significantly discourages financial investment, thereby stifling commercial expansion. Investors are frequently hesitant to allocate capital to research sectors where the route to market authorization remains undefined and hazardous. According to the Biotechnology Innovation Organization, in 2024, companies focused on infectious disease programs received only 3.4% of the total venture capital raised for biopharmaceutical companies over the preceding decade, creating a substantial funding gap that limits the resources available for phage developers to navigate the arduous regulatory landscape and effectively stalls the progression of promising therapeutic candidates into the commercial market.

Market Trends

The Integration of Artificial Intelligence for Phage Discovery is fundamentally altering the R&D landscape by accelerating the identification of viral candidates with high specificity. Developers are increasingly utilizing machine learning algorithms to screen vast genomic libraries and predict phage-host interactions, significantly reducing the time and cost associated with traditional wet-lab isolation methods. This technological advancement allows for the rapid generation of optimized cocktails capable of bypassing bacterial resistance mechanisms more efficiently than manual matching methods; validating this shift toward computational discovery, according to French Tech Journal, in October 2025, Phagos raised €25 million in a Series A funding round specifically to scale its AI-driven platform for developing evolving precision phage medicines.

Simultaneously, the Expansion into Veterinary and Agricultural Applications is broadening the market's scope beyond human therapeutics, driven by recent regulatory successes in the animal health sector. As restrictions on antibiotic usage in livestock tighten globally to combat One Health challenges, stakeholders are commercializing phage-based additives to ensure food safety and improve animal welfare. This sector is now witnessing tangible regulatory milestones that establish a pathway for broader commercial adoption; for instance, according to Intralytix, Inc., in September 2025, the company received formal approval from the U.S. Food and Drug Administration's Center for Veterinary Medicine for its Salmonella-specific bacteriophage preparation intended for use in pet food processing.

Key Market Players

• Armata Pharmaceuticals, Inc.
• iNtODEWORLD, Inc.
• Phage International, Inc.
• Fixed-Phage Limited
• OCUS BIOSCIENCES, INC.
• Intralytix, Inc
• PhagoMed Biopharma GmbH
• PHAGELUX, INC.
• Pherecydes Pharma SADIR
• Adaptive Phage Therapeutics Inc

Report Scope

In this report, the Global Phage Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phage Therapy Market, By Bacteria Type

• Salmonella
• Bacteriophage
• Streptococcus
• E.Coli
• Others

Phage Therapy Market, By Product

• Oral Consumption
• External Consumption
• Surgical Treatment

Phage Therapy Market, By Application

• Human Medicines
• Veterinary Sciences
• Food & Beverage
• Others

Phage Therapy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Phage Therapy Market.

Available Customizations:

Global Phage Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Phage Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Bacteria Type (Salmonella, Bacteriophage, Streptococcus, E.Coli, Others)
  • 5.2.2. By Product (Oral Consumption, External Consumption, Surgical Treatment)
  • 5.2.3. By Application (Human Medicines, Veterinary Sciences, Food & Beverage, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Phage Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Bacteria Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Phage Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Bacteria Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Phage Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Bacteria Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Phage Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Bacteria Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application

7. Europe Phage Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Bacteria Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Phage Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Bacteria Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
  • 7.3.2. France Phage Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Bacteria Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Phage Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Bacteria Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Phage Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Bacteria Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Phage Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Bacteria Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application

8. Asia Pacific Phage Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Bacteria Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Phage Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Bacteria Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
  • 8.3.2. India Phage Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Bacteria Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Phage Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Bacteria Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Phage Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Bacteria Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Phage Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Bacteria Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application

9. Middle East & Africa Phage Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Bacteria Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Phage Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Bacteria Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Phage Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Bacteria Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Phage Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Bacteria Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application

10. South America Phage Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Bacteria Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Phage Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Bacteria Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Phage Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Bacteria Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Phage Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Bacteria Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Phage Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Armata Pharmaceuticals, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. iNtODEWORLD, Inc.
• 15.3. Phage International, Inc.
• 15.4. Fixed-Phage Limited
• 15.5. OCUS BIOSCIENCES, INC.
• 15.6. Intralytix, Inc
• 15.7. PhagoMed Biopharma GmbH
• 15.8. PHAGELUX, INC.
• 15.9. Pherecydes Pharma SADIR
• 15.10. Adaptive Phage Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer